The aim of the project "InfraADC - Research infrastructure enabling research and development of drug-antibody conjugates (ADCs) as a new generation of targeted therapies in oncology" is a fundamental change in the production process, understood as a research process for the discovery and development of innovative oncological drugs, through the implementation of new technologies not previously used by the Company and adaptation of DMPK (bioanalytical), biochemical and biological laboratories, including by equipping with specialized research equipment and intangible and legal assets, to work on the technology of drug-antibody conjugates (DMPK). Antibody-Drug Conjugate, ADC). The objective of the project will be achieved through the purchase, installation and validation of a research infrastructure consisting of: - measuring equipment enabling the development of the above-mentioned methods, - software controlling and supporting the operation of these devices, - obtaining paid access to databases enabling the interpretation of certain measurements, - obtaining paid licenses for the use of certain biological materials (recombinant cell lines with stable expression of reporter systems). Antibody-Drug Conjugate, ADC) and strengthening the R&D potential of Ryvu. As part of the research agenda planned for 2025-2026, the Company plans to expand its portfolio of projects with ADC projects in oncology. ADC technology combines monoclonal antibodies and candidate drug molecules with a connector and applies a specific antibody targeting to transport drug molecules to target tissues, and as a result reduces systemic toxic drug side effects. An additional objective of the Project is to use the above infrastructure to support selected projects in Ryvu's preclinical portfolio. The technology will be permanently implemented in the Company's own operations.